119 related articles for article (PubMed ID: 31637484)
1. ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia.
Zhang X; Jin J; Yu W
Ann Hematol; 2019 Nov; 98(11):2621-2623. PubMed ID: 31637484
[No Abstract] [Full Text] [Related]
2. [Frequency and clinical features of ASXL2 gene mutation in acute myeloid leukemia patients with AML1- ETO fusion gene positive].
Zhao JX; Chen XH; Li JL; Pan J; Tan YH; Xu ZF; Ren FG; Zhang YF; Xu J; Li MQ; Li J; Zhang N; Chang JM; Wang XJ; Wang HW
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):676-81. PubMed ID: 27587249
[TBL] [Abstract][Full Text] [Related]
3. [Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene].
Cui P; Xu D; Xing T; Ren GH; Ma SM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):125-129. PubMed ID: 32027264
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
Zhang S; Zhou W; Li Y; Yu S; Xue M; Qiao Y; Jian J; Liu B; Wang D
Leuk Lymphoma; 2019 May; 60(5):1316-1319. PubMed ID: 30328750
[No Abstract] [Full Text] [Related]
5. [Acute myeloid leukemia (aml) subtype M2 with variation of the t (8;21)translocation and AML1/ETO expression].
Llimpe Y; Monteza R; Ticlahuanca J; Rubio P; Ortíz C; Arias A
Rev Peru Med Exp Salud Publica; 2013 Mar; 30(1):145-6. PubMed ID: 23612831
[No Abstract] [Full Text] [Related]
6. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Micol JB; Duployez N; Boissel N; Petit A; Geffroy S; Nibourel O; Lacombe C; Lapillonne H; Etancelin P; Figeac M; Renneville A; Castaigne S; Leverger G; Ifrah N; Dombret H; Preudhomme C; Abdel-Wahab O; Jourdan E
Blood; 2014 Aug; 124(9):1445-9. PubMed ID: 24973361
[TBL] [Abstract][Full Text] [Related]
7. JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Schnittger S; Bacher U; Kern W; Haferlach C; Haferlach T
Leukemia; 2007 Jan; 21(1):183-4. PubMed ID: 17096014
[No Abstract] [Full Text] [Related]
8. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.
Micol JB; Pastore A; Inoue D; Duployez N; Kim E; Lee SC; Durham BH; Chung YR; Cho H; Zhang XJ; Yoshimi A; Krivtsov A; Koche R; Solary E; Sinha A; Preudhomme C; Abdel-Wahab O
Nat Commun; 2017 May; 8():15429. PubMed ID: 28516957
[TBL] [Abstract][Full Text] [Related]
9. ASXL genes and RUNX1: an intimate connection?
Metzeler KH
Blood; 2014 Aug; 124(9):1382-3. PubMed ID: 25170110
[TBL] [Abstract][Full Text] [Related]
10. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
11. FACSorting help to analyze a rare case of acute myeloid leukemia with concurrent AML1-ETO and PML-RARA.
Chen M; Fu M; Wang A; Wu X; Zhen J; Gong M; Wu P; Du Q; Wang T; Liu H; Wang H
Int J Lab Hematol; 2021 Dec; 43(6):e276-e279. PubMed ID: 33943002
[No Abstract] [Full Text] [Related]
12. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
[TBL] [Abstract][Full Text] [Related]
14. [Correlations Between
Wang XM; Ye YX; Yang L; Lu XJ; Ying BW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):931-935. PubMed ID: 28598127
[TBL] [Abstract][Full Text] [Related]
15. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
[TBL] [Abstract][Full Text] [Related]
16. [Co-existence of AML1-ETO and BCR-ABL1 fusion genes in acute myeloid leukemia: a case report].
Yao YQ; Jia X; Liu H; Lu QS; Xiong WJ; Zhang Y; Liu QF; Shi PC
Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):203-206. PubMed ID: 38326048
[TBL] [Abstract][Full Text] [Related]
17. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
18. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
Liu H; Wang SA; Schlette EJ; Xu J; Jorgensen JL; Cameron Yin C; Li S; Jeffrey Medeiros L; Tang G
Ann Hematol; 2018 Oct; 97(10):1775-1783. PubMed ID: 29872884
[TBL] [Abstract][Full Text] [Related]
19. A novel exon in AML1-ETO negatively influences the clonogenic potential of the t(8;21) in acute myeloid leukemia.
Mannari D; Gascoyne D; Dunne J; Chaplin T; Young B
Leukemia; 2010 Apr; 24(4):891-4. PubMed ID: 20111069
[No Abstract] [Full Text] [Related]
20. RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature.
Lavallée VP; Lemieux S; Boucher G; Gendron P; Boivin I; Armstrong RN; Sauvageau G; Hébert J
Blood; 2016 May; 127(20):2498-501. PubMed ID: 26968532
[No Abstract] [Full Text] [Related]
[Next] [New Search]
